pembrolizumab Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	4924	1374853-91-4

Description:

Molecule	Description
Synonyms: pembrolizumab keytruda lambrolizumab SCH-900475 MK-3475	A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

pembrolizumab
keytruda
lambrolizumab
SCH-900475
MK-3475

A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Sept. 28, 2016	PMDA	MSD K.K.
July 17, 2015	EMA	Merck Sharp & Dohme Limited
Sept. 4, 2014	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1486.09	16.78	627	15741	64299	46605395
Product use in unapproved indication	574.93	16.78	370	15998	89903	46579791
Immune-mediated adverse reaction	509.95	16.78	85	16283	137	46669557
Pneumonitis	237.81	16.78	139	16229	28281	46641413
Immune-mediated hepatitis	190.64	16.78	44	16324	566	46669128
Hypothyroidism	178.24	16.78	120	16248	31218	46638476
Hepatitis	163.50	16.78	115	16253	32100	46637594
Colitis	152.66	16.78	117	16251	37230	46632464
Hypophysitis	150.09	16.78	43	16325	1350	46668344
Tubulointerstitial nephritis	136.10	16.78	77	16291	14711	46654983
Product use issue	133.37	16.78	165	16203	94479	46575215
Immune-mediated enterocolitis	132.90	16.78	30	16338	347	46669347
Autoimmune colitis	132.34	16.78	31	16337	427	46669267
Myocarditis	131.69	16.78	61	16307	7678	46662016
Tumour pseudoprogression	126.20	16.78	25	16343	144	46669550
Death	125.26	16.78	326	16042	335222	46334472
Autoimmune hypothyroidism	110.06	16.78	21	16347	96	46669598
Fulminant type 1 diabetes mellitus	105.03	16.78	23	16345	229	46669465
Adverse event	103.63	16.78	90	16278	34094	46635600
Thyroiditis	97.07	16.78	32	16336	1616	46668078
Off label use	96.57	16.78	322	16046	379519	46290175
Type 1 diabetes mellitus	93.34	16.78	36	16332	2874	46666820
Vitiligo	92.87	16.78	28	16340	1053	46668641
Immune-mediated hypothyroidism	85.51	16.78	13	16355	6	46669688
Adrenal insufficiency	83.66	16.78	54	16314	13070	46656624
Autoimmune hepatitis	80.95	16.78	44	16324	7770	46661924
Adrenocorticotropic hormone deficiency	76.00	16.78	17	16351	188	46669506
Hyperthyroidism	74.19	16.78	48	16320	11663	46658031
Nephritis	69.30	16.78	26	16342	1924	46667770
Lichenoid keratosis	67.44	16.78	23	16345	1290	46668404
Autoimmune thyroiditis	65.37	16.78	28	16340	2927	46666767
Myasthenia gravis	64.24	16.78	29	16339	3437	46666257
Immune-mediated arthritis	59.30	16.78	9	16359	4	46669690
Immune-mediated myocarditis	58.93	16.78	10	16358	19	46669675
Drug hypersensitivity	58.72	16.78	8	16360	243817	46425877
Immune-mediated pancreatitis	58.06	16.78	11	16357	48	46669646
Myositis	56.57	16.78	35	16333	7869	46661825
Cholestasis	55.06	16.78	57	16311	26836	46642858
Metastatic malignant melanoma	51.72	16.78	19	16349	1325	46668369
Inappropriate schedule of product administration	51.11	16.78	86	16282	64927	46604767
Therapy partial responder	50.27	16.78	27	16341	4655	46665039
Autoimmune arthritis	49.90	16.78	9	16359	28	46669666
Secondary adrenocortical insufficiency	47.58	16.78	16	16352	859	46668835
Hepatocellular injury	47.28	16.78	55	16313	29467	46640227
Drug ineffective	46.61	16.78	106	16262	677732	45991962
Immune-mediated hepatic disorder	46.54	16.78	8	16360	17	46669677
Drug effective for unapproved indication	45.65	16.78	18	16350	1524	46668170
Polymyalgia rheumatica	44.69	16.78	20	16348	2322	46667372
Immune-mediated thyroiditis	43.36	16.78	7	16361	8	46669686
Hypopituitarism	42.01	16.78	14	16354	731	46668963
Uveitis	41.84	16.78	30	16338	8611	46661083
Immune-mediated dermatitis	41.74	16.78	6	16362	0	46669694
Diabetic ketoacidosis	41.67	16.78	41	16327	18169	46651525
Immune-mediated nephritis	41.17	16.78	8	16360	41	46669653
Autoimmune nephritis	39.35	16.78	11	16357	315	46669379
Immune-mediated hyperthyroidism	39.31	16.78	6	16362	3	46669691
Autoimmune pancreatitis	38.91	16.78	10	16358	206	46669488
Rheumatoid arthritis	37.06	16.78	19	16349	240196	46429498
Pyrexia	36.67	16.78	228	16140	348574	46321120
Lichen planus	36.09	16.78	16	16352	1817	46667877
Lymphocytic hypophysitis	35.37	16.78	9	16359	178	46669516
Fall	35.36	16.78	38	16330	329059	46340635
Metastases to central nervous system	34.90	16.78	30	16338	11191	46658503
Eosinophilic fasciitis	34.79	16.78	8	16360	101	46669593
Hepatic function abnormal	34.62	16.78	51	16317	34370	46635324
Dizziness	33.67	16.78	42	16326	340372	46329322
Drug interaction	32.94	16.78	15	16353	203079	46466615
Pemphigoid	32.81	16.78	22	16346	5669	46664025
Neurofibrosarcoma	32.15	16.78	8	16360	144	46669550
Tumour associated fever	31.45	16.78	8	16360	158	46669536
Amputation stump pain	30.83	16.78	6	16362	31	46669663
Subacute cutaneous lupus erythematosus	29.20	16.78	14	16354	1901	46667793
Polyglandular autoimmune syndrome type II	29.03	16.78	6	16362	44	46669650
Nasopharyngitis	28.93	16.78	9	16359	153989	46515705
Hepatitis toxic	28.61	16.78	16	16352	2984	46666710
Autoimmune myocarditis	28.15	16.78	6	16362	52	46669642
Immune-mediated endocrinopathy	27.83	16.78	4	16364	0	46669694
Autoimmune endocrine disorder	27.83	16.78	4	16364	0	46669694
Transaminases increased	27.72	16.78	41	16327	27720	46641974
Blood thyroid stimulating hormone increased	27.55	16.78	20	16348	5849	46663845
Exposure during pregnancy	27.36	16.78	3	16365	108209	46561485
Joint swelling	27.34	16.78	12	16356	166061	46503633
Interstitial lung disease	27.08	16.78	59	16309	53890	46615804
Oligodipsia	26.00	16.78	5	16363	24	46669670
Immune-mediated neuropathy	25.59	16.78	4	16364	3	46669691
Radiation pneumonitis	24.83	16.78	11	16357	1246	46668448
Aspartate aminotransferase increased	24.71	16.78	72	16296	78628	46591066
Silent thyroiditis	24.52	16.78	5	16363	34	46669660
Sinusitis	23.63	16.78	8	16360	129760	46539934
Alanine aminotransferase increased	23.20	16.78	76	16292	88375	46581319
Skin toxicity	23.19	16.78	15	16353	3639	46666055
Autoimmune dermatitis	23.09	16.78	5	16363	47	46669647
Pericardial effusion	23.06	16.78	36	16332	25507	46644187
Pulmonary embolism	23.05	16.78	87	16281	108498	46561196
Antinuclear antibody	22.60	16.78	8	16360	501	46669193
Headache	22.51	16.78	89	16279	478263	46191431
Toxic epidermal necrolysis	22.38	16.78	33	16335	22245	46647449
Drug intolerance	22.11	16.78	12	16356	147037	46522657
Toxicity to various agents	22.11	16.78	25	16343	211741	46457953
Meningitis aseptic	21.76	16.78	15	16353	4044	46665650
Pulmonary sarcoidosis	21.69	16.78	9	16359	869	46668825
Autoimmune uveitis	21.60	16.78	4	16364	15	46669679
Vesical fistula	21.14	16.78	5	16363	72	46669622
Overdose	20.95	16.78	5	16363	101974	46567720
Hepatotoxicity	20.87	16.78	34	16334	24975	46644719
Sarcoidosis	20.69	16.78	16	16352	5143	46664551
Melanoma recurrent	20.59	16.78	5	16363	81	46669613
Neoplasm progression	20.56	16.78	35	16333	26648	46643046
Cholangitis sclerosing	20.43	16.78	9	16359	1006	46668688
Cytokine release syndrome	20.09	16.78	17	16351	6206	46663488
Asthma	19.79	16.78	4	16364	91538	46578156
Rash maculo-papular	19.44	16.78	35	16333	27839	46641855
Nephropathy toxic	19.36	16.78	18	16350	7436	46662258
Thyroid hormones increased	19.19	16.78	6	16362	255	46669439
Loss of consciousness	19.15	16.78	7	16361	108231	46561463
Abdominal discomfort	19.11	16.78	15	16353	151150	46518544
Renal tubular necrosis	18.84	16.78	21	16347	10738	46658956
Urogenital fistula	18.57	16.78	5	16363	124	46669570
Bronchitis	18.50	16.78	7	16361	105972	46563722
Cholecystitis	18.39	16.78	24	16344	14442	46655252
Serous retinal detachment	18.39	16.78	5	16363	129	46669565
Adenocarcinoma	18.30	16.78	11	16357	2348	46667346
Blood pressure abnormal	18.29	16.78	22	16346	12195	46657499
Immune-mediated myositis	18.05	16.78	8	16360	908	46668786
Pleural effusion	18.04	16.78	67	16301	82885	46586809
Vital functions abnormal	17.97	16.78	6	16362	315	46669379
No adverse event	17.82	16.78	38	16330	34193	46635501
Condition aggravated	17.82	16.78	37	16331	245015	46424679
Cholangitis	17.68	16.78	14	16354	4660	46665034
SJS-TEN overlap	17.60	16.78	5	16363	152	46669542
Achromotrichia acquired	17.58	16.78	3	16365	6	46669688
Radiation associated pain	17.51	16.78	4	16364	49	46669645
Pneumonia moraxella	17.51	16.78	4	16364	49	46669645
Cheilitis	17.39	16.78	13	16355	3975	46665719
Autoimmune thyroid disorder	17.26	16.78	3	16365	7	46669687
Roseolovirus test positive	17.15	16.78	4	16364	54	46669640
Myasthenia gravis crisis	17.00	16.78	6	16362	373	46669321

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1921.10	15.40	984	21981	71303	29858210
Immune-mediated adverse reaction	912.45	15.40	176	22789	300	29929213
Product use in unapproved indication	475.86	15.40	417	22548	73276	29856237
Pneumonitis	390.84	15.40	250	22715	27204	29902309
Interstitial lung disease	309.11	15.40	300	22665	59897	29869616
Adverse event	213.92	15.40	138	22827	15203	29914310
Myasthenia gravis	213.70	15.40	82	22883	2910	29926603
Adrenal insufficiency	202.16	15.40	116	22849	10347	29919166
Hypothyroidism	190.10	15.40	127	22838	14836	29914677
Immune-mediated hepatitis	187.47	15.40	58	22907	1058	29928455
Product use issue	181.13	15.40	199	22766	45817	29883696
Immune-mediated enterocolitis	177.53	15.40	55	22910	1008	29928505
Colitis	164.33	15.40	157	22808	30663	29898850
Type 1 diabetes mellitus	157.36	15.40	70	22895	3629	29925884
Off label use	156.83	15.40	482	22483	248808	29680705
Myocarditis	154.37	15.40	96	22869	9915	29919598
Tumour pseudoprogression	151.17	15.40	38	22927	306	29929207
Hypophysitis	150.80	15.40	56	22909	1812	29927701
Immune-mediated myocarditis	147.59	15.40	29	22936	57	29929456
Autoimmune hepatitis	139.57	15.40	64	22901	3563	29925950
Autoimmune colitis	127.22	15.40	40	22925	771	29928742
Vitiligo	120.20	15.40	37	22928	663	29928850
Immune-mediated hypothyroidism	114.53	15.40	19	22946	3	29929510
Myositis	110.41	15.40	79	22886	10298	29919215
Immune-mediated hepatic disorder	108.73	15.40	21	22944	36	29929477
Therapy partial responder	102.25	15.40	52	22913	3639	29925874
Tubulointerstitial nephritis	100.77	15.40	94	22871	17797	29911716
Pemphigoid	98.24	15.40	65	22900	7463	29922050
Hyperthyroidism	89.26	15.40	63	22902	8035	29921478
Immune-mediated arthritis	85.40	15.40	16	22949	21	29929492
Thyroiditis	79.61	15.40	34	22931	1595	29927918
Drug interaction	79.52	15.40	27	22938	199541	29729972
Immune-mediated myositis	73.49	15.40	30	22935	1255	29928258
Adrenocorticotropic hormone deficiency	70.36	15.40	22	22943	416	29929097
Inappropriate schedule of product administration	68.40	15.40	115	22850	39613	29889900
Death	68.15	15.40	487	22478	356796	29572717
Hepatitis	66.75	15.40	84	22881	22272	29907241
Nephritis	65.15	15.40	32	22933	2078	29927435
Completed suicide	63.69	15.40	3	22962	99489	29830024
Polymyalgia rheumatica	60.74	15.40	25	22940	1068	29928445
Fall	53.58	15.40	37	22928	181835	29747678
Organising pneumonia	52.52	15.40	38	22927	5036	29924477
Autoimmune hypothyroidism	52.45	15.40	11	22954	34	29929479
Autoimmune thyroiditis	52.20	15.40	22	22943	998	29928515
Hypopituitarism	51.57	15.40	25	22940	1577	29927936
Autoimmune arthritis	51.29	15.40	11	22954	39	29929474
Overdose	46.94	15.40	5	22960	84332	29845181
Immune-mediated uveitis	46.85	15.40	8	22957	3	29929510
Hepatic function abnormal	46.85	15.40	101	22864	41844	29887669
Secondary adrenocortical insufficiency	45.68	15.40	20	22945	997	29928516
Autoimmune myocarditis	45.59	15.40	12	22953	118	29929395
Metastatic malignant melanoma	45.52	15.40	25	22940	2045	29927468
Diabetic ketoacidosis	44.46	15.40	58	22907	15928	29913585
Eyelid ptosis	42.95	15.40	34	22931	5154	29924359
Fulminant type 1 diabetes mellitus	42.63	15.40	16	22949	533	29928980
Cholangitis sclerosing	41.02	15.40	18	22947	902	29928611
Immune-mediated thyroiditis	40.73	15.40	7	22958	3	29929510
Lichenoid keratosis	39.84	15.40	23	22942	2071	29927442
Immune-mediated pancreatitis	39.39	15.40	8	22957	20	29929493
Lymphocytic hypophysitis	38.52	15.40	11	22954	150	29929363
Autoimmune nephritis	37.36	15.40	11	22954	168	29929345
Rash	37.19	15.40	263	22702	191626	29737887
Hepatocellular injury	36.42	15.40	68	22897	25403	29904110
Haemophagocytic lymphohistiocytosis	36.14	15.40	41	22924	9750	29919763
Lung disorder	35.39	15.40	76	22889	31393	29898120
Diarrhoea	35.33	15.40	401	22564	333702	29595811
Drug effective for unapproved indication	34.92	15.40	17	22948	1082	29928431
Encephalitis autoimmune	34.64	15.40	13	22952	433	29929080
Pneumonia bacterial	34.07	15.40	39	22926	9364	29920149
Immune thrombocytopenia	33.63	15.40	35	22930	7556	29921957
Encephalitis	32.77	15.40	32	22933	6404	29923109
Autoimmune pancreatitis	32.52	15.40	11	22954	269	29929244
Immune-mediated dermatitis	31.97	15.40	6	22959	8	29929505
Toxicity to various agents	31.26	15.40	55	22910	177128	29752385
Immune-mediated endocrinopathy	30.87	15.40	5	22960	0	29929513
Paraneoplastic neurological syndrome	30.81	15.40	6	22959	11	29929502
Tumour hyperprogression	30.81	15.40	6	22959	11	29929502
Dizziness	30.48	15.40	65	22900	194844	29734669
Immune-mediated nephritis	29.58	15.40	8	22957	88	29929425
Immune-mediated renal disorder	28.52	15.40	5	22960	3	29929510
Autoimmune uveitis	28.52	15.40	5	22960	3	29929510
Skin toxicity	28.42	15.40	22	22943	3227	29926286
Melanoma recurrent	28.36	15.40	8	22957	104	29929409
Neoplasm progression	28.15	15.40	50	22915	17973	29911540
Silent thyroiditis	27.82	15.40	6	22959	22	29929491
Metastases to central nervous system	27.73	15.40	31	22934	7253	29922260
Immune-mediated encephalitis	27.61	15.40	6	22959	23	29929490
Thyroid disorder	27.35	15.40	20	22945	2694	29926819
Cancer pain	26.49	15.40	19	22946	2483	29927030
Plasma cell myeloma	25.50	15.40	5	22960	53457	29876056
Haemoglobin decreased	25.45	15.40	30	22935	114068	29815445
Drug ineffective	24.95	15.40	156	22809	340231	29589282
Enteritis	24.82	15.40	28	22937	6617	29922896
Drug hypersensitivity	24.37	15.40	11	22954	68508	29861005
Eosinophilic fasciitis	24.08	15.40	7	22958	102	29929411
Hypotension	23.65	15.40	77	22888	200488	29729025
Headache	23.62	15.40	67	22898	182239	29747274
Hypothalamo-pituitary disorder	23.60	15.40	11	22954	635	29928878
Cutaneous sarcoidosis	23.53	15.40	7	22958	111	29929402
Rheumatoid nodule	23.03	15.40	15	22950	1675	29927838
Anxiety	23.00	15.40	21	22944	89850	29839663
Insomnia	22.51	15.40	23	22942	93313	29836200
Depression	22.13	15.40	22	22943	90415	29839098
Decreased appetite	22.10	15.40	193	22772	149717	29779796
Pulmonary sarcoidosis	21.48	15.40	10	22955	576	29928937
Hospitalisation	21.44	15.40	4	22961	44315	29885198
Cardiac arrest	21.14	15.40	24	22941	92826	29836687
Dermatomyositis	21.12	15.40	12	22953	1048	29928465
Colitis microscopic	20.52	15.40	14	22951	1689	29927824
Lichen planus	20.39	15.40	11	22954	868	29928645
Agitation	20.32	15.40	8	22957	54065	29875448
Pericarditis malignant	20.31	15.40	4	22961	8	29929505
Primary hypothyroidism	20.03	15.40	5	22960	39	29929474
Mucosal inflammation	19.96	15.40	60	22905	30434	29899079
Latent autoimmune diabetes in adults	19.70	15.40	5	22960	42	29929471
Cholangitis	19.68	15.40	27	22938	7775	29921738
Autoimmune neuropathy	19.49	15.40	5	22960	44	29929469
Respiratory failure	19.47	15.40	138	22827	100504	29829009
Lymph node abscess	19.16	15.40	4	22961	12	29929501
Adrenalitis	19.16	15.40	4	22961	12	29929501
Pancreatic failure	19.09	15.40	10	22955	744	29928769
Transitional cell carcinoma recurrent	18.69	15.40	4	22961	14	29929499
Tumour ulceration	18.66	15.40	5	22960	53	29929460
Pyrexia	18.65	15.40	323	22642	294166	29635347
Non-small cell lung cancer stage III	18.52	15.40	3	22962	0	29929513
Autoimmune cholangitis	18.52	15.40	3	22962	0	29929513
Optic neuritis	18.21	15.40	17	22948	3217	29926296
Cardiac tamponade	18.08	15.40	20	22945	4624	29924889
International normalised ratio increased	18.04	15.40	7	22958	47732	29881781
Drug-induced liver injury	18.02	15.40	46	22919	21228	29908285
Fatigue	17.96	15.40	345	22620	320328	29609185
Limbic encephalitis	17.75	15.40	7	22958	267	29929246
Pleural effusion	17.63	15.40	107	22858	73959	29855554
Blood corticotrophin decreased	17.50	15.40	6	22959	153	29929360
Hallucination	17.25	15.40	8	22957	49051	29880462
Hepatotoxicity	17.24	15.40	41	22924	18104	29911409
Hypersensitivity	17.23	15.40	10	22955	54018	29875495
Syncope	17.19	15.40	24	22941	84879	29844634
Bradycardia	17.14	15.40	15	22950	65511	29864002
Hepatitis E virus test positive	17.08	15.40	4	22961	23	29929490
Autoimmune disorder	17.02	15.40	12	22953	1527	29927986
Cachexia	16.86	15.40	23	22942	6588	29922925
Toxic epidermal necrolysis	16.47	15.40	40	22925	17900	29911613
Radiation pneumonitis	16.35	15.40	13	22952	1983	29927530
Pain in extremity	16.18	15.40	38	22927	110183	29819330
Non-small cell lung cancer	16.17	15.40	17	22948	3713	29925800
Transaminases increased	16.15	15.40	47	22918	23410	29906103
Pruritus	15.78	15.40	149	22816	118055	29811458
Metastases to skin	15.55	15.40	7	22958	373	29929140
Melaena	15.54	15.40	3	22962	32434	29897079
Liver disorder	15.40	15.40	54	22911	29668	29899845

Pharmacologic Action:

Source	Code	Description
ATC	L01XC18	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Monoclonal antibodies
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
FDA MoA	N0000191259	Programmed Death Receptor-1-directed Antibody Interactions
FDA EPC	N0000191260	Programmed Death Receptor-1 Blocking Antibody

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer	indication	254637007	DOID:3908
Malignant tumor of head and/or neck	indication	255056009
Metastatic malignant melanoma	indication	443493003
Metastatic renal cell carcinoma	indication	702392008

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Programmed cell death protein 1	Membrane receptor	Q15116	PDCD1_HUMAN	ANTIBODY BINDING	Kd	10		IUPHAR	DRUG LABEL

External reference:

ID	Source
D10574	KEGG_DRUG
4033703	VUID
N0000191088	NUI
4033703	VANDF
C3855203	UMLSCUI
CHEMBL3137343	ChEMBL_ID
DB09037	DRUGBANK_ID
C582435	MESH_SUPPLEMENTAL_RECORD_UI
7499	IUPHAR_LIGAND_ID
9798	INN_ID
DPT0O3T46P	UNII
1547545	RXNORM
228586	MMSL
30533	MMSL
d08287	MMSL
015666	NDDF
716125002	SNOMEDCT_US
763541003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KEYTRUDA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3026	INJECTION, SOLUTION	25 mg	INTRAVENOUS	BLA	28 sections
KEYTRUDA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3026	INJECTION, SOLUTION	25 mg	INTRAVENOUS	BLA	28 sections
KEYTRUDA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3029	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	BLA	28 sections
KEYTRUDA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3029	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	BLA	28 sections